skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 21 - 40 of 821  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
previous page 1 Results 2 3 4 5 next page
Refined by: Database: HighWire Press (Free Journals) remove
Result Number Material Type Add to My Shelf Action Record Details and Options
21
POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
Material Type:
Article 		Add to My Research

POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1139-1140 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3273

Full text available

Citations Cited by
22
FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY
FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY
Material Type:
Article 		Add to My Research

FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.623-623 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2020-eular.2367

Full text available

Citations Cited by
23
OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa
OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa
Material Type:
Article 		Add to My Research

OP0165 A neoepitope fragment of c-reactive protein is prognostic of radiographic knee oa

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.120 [Peer Reviewed Journal]

2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2017 © 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-eular.6290

Full text available

Citations Cited by
24
FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
Material Type:
Article 		Add to My Research

FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM

Annals of the rheumatic diseases, 2019-06, Vol.78 (Suppl 2), p.878-879 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2019-eular.2829

Full text available

Citations Cited by
25
AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS
AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS
Material Type:
Article 		Add to My Research

AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1507-1507 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2719

Full text available

Citations Cited by
26
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1696-1697 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2790

Full text available

Citations Cited by
27
POS0514 BONE EROSION REMODELING AFTER DEPLETION OF MONOSODIUM URATE DEPOSITION WITH INTENSIVE URATE-LOWERING WITH PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT: MIRROR RCT DUAL-ENERGY CT FINDINGS
POS0514 BONE EROSION REMODELING AFTER DEPLETION OF MONOSODIUM URATE DEPOSITION WITH INTENSIVE URATE-LOWERING WITH PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT: MIRROR RCT DUAL-ENERGY CT FINDINGS
Material Type:
Article 		Add to My Research

POS0514 BONE EROSION REMODELING AFTER DEPLETION OF MONOSODIUM URATE DEPOSITION WITH INTENSIVE URATE-LOWERING WITH PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT: MIRROR RCT DUAL-ENERGY CT FINDINGS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.519-520 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2396

Full text available

Citations Cited by
28
POS1544 LONG-TERM SAFETY AND EFFICACY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS BY PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG EXPOSURE
POS1544 LONG-TERM SAFETY AND EFFICACY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS BY PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG EXPOSURE
Material Type:
Article 		Add to My Research

POS1544 LONG-TERM SAFETY AND EFFICACY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS BY PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG EXPOSURE

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1140-1141 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3308

Full text available

Citations Cited by
29
POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY
POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY
Material Type:
Article 		Add to My Research

POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1137-1137 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2581

Full text available

Citations Cited by
30
AB0482 CLINICAL SAFETY AND FEASIBILITY OF A NOVEL IMPLANTABLE NEUROIMMUNE MODULATION DEVICE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
AB0482 CLINICAL SAFETY AND FEASIBILITY OF A NOVEL IMPLANTABLE NEUROIMMUNE MODULATION DEVICE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Material Type:
Article 		Add to My Research

AB0482 CLINICAL SAFETY AND FEASIBILITY OF A NOVEL IMPLANTABLE NEUROIMMUNE MODULATION DEVICE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1435-1435 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5077

Full text available

Citations Cited by
31
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Material Type:
Article 		Add to My Research

AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1782-1783 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.642

Full text available

Citations Cited by
32
POS0529 USING SOCIAL MEDIA CONVERSATIONS TO UNDERSTAND PATIENT CARE: FACTORS DRIVING PROACTIVE VS REACTIVE MANAGEMENT OF GOUT
POS0529 USING SOCIAL MEDIA CONVERSATIONS TO UNDERSTAND PATIENT CARE: FACTORS DRIVING PROACTIVE VS REACTIVE MANAGEMENT OF GOUT
Material Type:
Article 		Add to My Research

POS0529 USING SOCIAL MEDIA CONVERSATIONS TO UNDERSTAND PATIENT CARE: FACTORS DRIVING PROACTIVE VS REACTIVE MANAGEMENT OF GOUT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.528-529 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1625

Full text available

Citations Cited by
33
POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY
Material Type:
Article 		Add to My Research

POS0573 COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.555-556 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3966

Full text available

Citations Cited by
34
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY
Material Type:
Article 		Add to My Research

POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.729-730 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3572

Full text available

Citations Cited by
35
OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
Material Type:
Article 		Add to My Research

OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.27-28 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2688

Full text available

Citations Cited by
36
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
Material Type:
Article 		Add to My Research

AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1775-1776 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1671

Full text available

Citations Cited by
37
AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY
Material Type:
Article 		Add to My Research

AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1765-1766 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2516

Full text available

Citations Cited by
38
POS0803-HPR DEVELOPMENT OF A PATIENT-CENTERED MULTIMODAL DISEASE MANAGEMENT PLATFORM FOR THE FIBROMYALGIA-LIKE POST-COVID19 SYNDROME
POS0803-HPR DEVELOPMENT OF A PATIENT-CENTERED MULTIMODAL DISEASE MANAGEMENT PLATFORM FOR THE FIBROMYALGIA-LIKE POST-COVID19 SYNDROME
Material Type:
Article 		Add to My Research

POS0803-HPR DEVELOPMENT OF A PATIENT-CENTERED MULTIMODAL DISEASE MANAGEMENT PLATFORM FOR THE FIBROMYALGIA-LIKE POST-COVID19 SYNDROME

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.696-696 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3065

Full text available

Citations Cited by
39
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
Material Type:
Article 		Add to My Research

POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1123-1123 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3268

Full text available

Citations Cited by
40
POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS
POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS
Material Type:
Article 		Add to My Research

POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.499-499 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.4095

Full text available

Citations Cited by

Results 21 - 40 of 821  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
previous page 1 Results 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 1998  (10)
  2. 1998 To 2004  (15)
  3. 2005 To 2010  (12)
  4. 2011 To 2016  (46)
  5. After 2016  (739)
  6. More options open sub menu

Language 

  1. Japanese  (2)
  2. Norwegian  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait